P53 in skin cancer: From a master player to a privileged target for prevention and therapy

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2020

Autores

Loureiro, JB (Autor) Outra; Abrantes, M (Autor) Outra; Oliveira, PA (Autor) Outra; Lucilia Saraiva (Autor) FFUP

Revista

Título: Biochimica et Biophysica Acta - Reviews on Cancer

Vol. 1874

ISSN: 0304-419X

Editora: Elsevier

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 3 Citações

Outras Informações

ID Authenticus: P-00S-TER

DOI: 10.1016/j.bbcan.2020.188438

Abstract (EN): resistance mechanisms have imposed the pursuit for new therapeutic alternatives. Moreover, additional preventive strategies should be adopted to strengthen prevention and reduce the rising number of newly SC cases. This review provides relevant insights on the role of p53 tumour suppressor protein in melanoma and nonmelanoma skin carcinogenesis, also highlighting the therapeutic potential of p53-targeting drugs against SC. In fact, several evidences are provided demonstrating the encouraging outcomes achieved with p53-activating drugs, alone and in combination with currently available therapies in SC. Another pertinent perspective falls on targeting p53 mutations, as molecular signatures in premature phases of photocarcinogenesis, in future SC preventive approaches. Overall, this review affords a critical and timely discussion of relevant issues related to SC prevention and therapy. Importantly, it paves the way to future studies that may boost the clinical translation of p53-activating agents, making them new effective alternatives in precision medicine of SC therapy and prevention.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 10